JT develops pharmaceutical therapies for metabolic diseases, autoimmune/inflammatory diseases and viral infection. In 2018, JT reported net sales of 114 billion yen (€ 1 billion) and close to 40 billion yen (€ 330M) R&D investment with 2,000 employees in its pharmaceutical business.